Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United States.
Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
1d
Daughter's warning after fitness coach dad died from lung disease at 69
Denham Thomas, from Hartlepool, saw his life drastically altered by Chronic Obstructive Pulmonary Disease, becoming dependent ...
3h
Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80%
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
Yicai Global
11h
AstraZeneca Doubles Down on Chronic, Rare Disease Innovation in China
(Yicai) Sept. 30 -- AstraZeneca will strengthen its commitment to researching chronic and rare diseases in China, driving ...
3d
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
Rising Kashmir
11d
Understanding COPD: A Chronic Lung Disease
Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...
In Depth
3d
on MSN
In Depth
Exclusive: Understanding Chronic Lung Diseases And Co-Morbidities
MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...
Too Old to Operate
14d
Enhancing Pulmonary Rehabilitation in COPD with Virtual Reality
The following is a summary of “Virtual reality for COPD exacerbation: A randomized controlled trial,” published in the August ...
The Pharma Letter
3h
M&A activity – new inflammatory disease targets fuelling investment interest
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...
News Medical
17h
Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery
Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and ...
5d
Commit To Care: The Power of Adherence In Chronic Respiratory Disease Treatment
With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Regeneron
Dupixent
Sanofi
Food and Drug Administration
Feedback